Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
04-06 Hyoscine
| Hyoscine Hydrobromide |
|
Formulary
|
Tablets 300micrograms Hyoscine patches are currently unavailable. Healthcare professionals in primary and secondary care should not initiate any new patients on hyoscine hydrobromide (Scopoderm) 1.5mg patches, see: https://www.sps.nhs.uk/shortages/shortage-of-hyoscine-hydrobromide-scopoderm-1-5mg-patches/ |
 MHRA: Hyoscine hydrobromide patches (Scopoderm 1.5mg Patch or Scopoderm TTS Patch): risk of anticholinergic side effects, including hyperthermia |
|
Links
- Hypersalivation – can hyoscine hydrobromide be used to treat it?
- Hypersalivation treatment options
LSCMMG: Doxylamine and Pyridoxine NMR- LSCMMG: Opioid reduction: best interests opioid reduction position statement
- LSCMMG: Opioid treatment: patient-prescriber opioid treatment agreement
- LSCMMG: Restless Legs Syndrome in Adults in Primary Care
- MHRA Drug Safety Update April 2016: Apomorphine with domperidone: minimising risk of cardiac side effects
- MHRA Drug Safety Update Dec 2019: Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents
- MHRA Dug Safety Update Jan 2020: Ondansetron in pregnancy – small increased risk of oral clefts following use in the first 12 weeks of pregnancy
- MHRA update on restricted dose information (Aug 13)
- MHRA: Advice for domperidone (April 2014)
- MHRA: Apomorphine with domperidone: minimising risk of cardiac side effects
- MHRA: Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents
- MHRA: Domperidone: risks of cardiac side effects
- MHRA: Hyoscine hydrobromide patches (Scopoderm 1.5mg Patch or Scopoderm TTS Patch): risk of anticholinergic side effects, including hyperthermia
- MHRA: Metoclopramide: risk of neurological adverse effects
- MHRA: Ondansetron for intravenous use: dose-dependent QT interval prolongation
- MHRA: Ondansetron for intravenous use: dose-dependent QT interval prolongation
- MHRA: Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy
- MHRA: Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy
- NICE CG150: Headaches in over 12s: diagnosis and management
- NICE TA:919 Rimegepant for treating migraine
- NICE: Management of vomiting in children and young people with gastroenteritis: ondansetron
- Ondansetron for vomiting in children with gastroenteritis- NICE evidence summary
- RCOG: The Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No.69)
- UKMI: Domperidone - New restrictions in GI conditions (May 2014)